Chemoresistance‑associated alternative splicing signatures in serous ovarian cancer

Sun,Tianshui; Sun,Tianshui; Sun,Tianshui; Yang,Qing; Yang,Qing; Yang,Qing

doi:10.3892/ol.2020.11562

Chemoresistance‑associated alternative splicing signatures in serous ovarian cancer

Authors:
- Tianshui Sun
- Qing Yang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: April 21, 2020 https://doi.org/10.3892/ol.2020.11562
Pages: 420-430

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary platinum-based chemoresistance occurs in ~30% of patients with serous ovarian cancer. Chemoresistance is the main cause of disease recurrence, and accurate predictors to identify these patients with chemoresistance are required. Alternative splicing (AS) is a post‑transcriptional modification process that is altered in cancer. A possible association between AS and chemoresistance is unclear and needs to be studied comprehensively in ovarian cancer. In the present study, RNA‑sequencing data and clinical information for 320 patients with ovarian serous cystadenocarcinoma (OV) were downloaded from The Cancer Genome Atlas (TCGA) database. Splicing events were determined using the TCGA SpliceSeq tool. Seven types of AS events were identified. Univariate and multivariate logistic analyses were performed, and predictive models for OV chemoresistance were established, as well as a splicing network. A total of 22,036 AS events were identified in 7,404 genes, with 915 AS events detected in 677 genes that were significantly associated with chemoresistance in patients with OV. A receiver operating characteristic (ROC) curve was constructed for resistance predictive models composed of the most significant AS events. The area under the ROC curve was 0.931, indicating strong and efficient prediction of chemoresistance. Additionally, the high‑risk score was associated with shorter overall survival. The splicing correlation network suggested a potential role of splicing factors in chemoresistance. In summary, the present study created a powerful predictor for primary platinum‑based chemoresistance in patients with OV, identified splicing networks that could be involved in potential mechanisms of chemoresistance and provided potential targets to overcome chemoresistance.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296. 2018. View Article : Google Scholar : PubMed/NCBI
4	Jessmon P, Boulanger T, Zhou W and Patwardhan P: Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther. 17:427–437. 2017. View Article : Google Scholar : PubMed/NCBI
5	Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al: Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 15:668–679. 2015. View Article : Google Scholar : PubMed/NCBI
6	Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, Lu S, Fuentes E, Huw LY, Lackner MR, et al: Upregulation of Periostin and reactive Stroma is associated with primary chemoresistance and predicts clinical outcomes in epithelial ovarian cancer. Clin Cancer Res. 21:2941–2951. 2015. View Article : Google Scholar : PubMed/NCBI
7	Muñoz-Galván S, Felipe-Abrio B, García-Carrasco M, Domínguez-Piñol J, Suarez-Martinez E, Verdugo-Sivianes EM, Espinosa-Sánchez A, Navas LE, Otero-Albiol D, Marin JJ, et al: New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools. J Exp Clin Cancer Res. 38:2342019. View Article : Google Scholar : PubMed/NCBI
8	van Zyl B, Tang D and Bowden NA: Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment. Endocr Relat Cancer. 25:R303–R318. 2018. View Article : Google Scholar : PubMed/NCBI
9	Shu T, Li Y, Wu X, Li B and Liu Z: Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment. Cancer Lett. 411:65–73. 2017. View Article : Google Scholar : PubMed/NCBI
10	Bai L, Wang A, Zhang Y, Xu X and Zhang X: Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Exp Cell Res. 366:161–171. 2018. View Article : Google Scholar : PubMed/NCBI
11	Bai H, Cao D, Yang J, Li M, Zhang Z and Shen K: Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med. 20:581–593. 2016. View Article : Google Scholar : PubMed/NCBI
12	Konecny GE, Winterhoff B and Wang C: Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification. Gynecol Oncol. 141:379–385. 2016. View Article : Google Scholar : PubMed/NCBI
13	Chon HS and Lancaster JM: Microarray-based gene expression studies in ovarian cancer. Cancer Control. 18:8–15. 2011. View Article : Google Scholar : PubMed/NCBI
14	Salton M and Misteli T: Small molecule modulators of Pre-mRNA splicing in cancer therapy. Trends Mol Med. 22:28–37. 2016. View Article : Google Scholar : PubMed/NCBI
15	Narayanan SP, Singh S and Shukla S: A saga of cancer epigenetics: Linking epigenetics to alternative splicing. Biochem J. 474:885–896. 2017. View Article : Google Scholar : PubMed/NCBI
16	Nilsen TW and Graveley BR: Expansion of the eukaryotic proteome by alternative splicing. Nature. 463:457–463. 2010. View Article : Google Scholar : PubMed/NCBI
17	Nakka K, Ghigna C, Gabellini D and Dilworth FJ: Diversification of the muscle proteome through alternative splicing. Skelet Muscle. 8:82018. View Article : Google Scholar : PubMed/NCBI
18	Chang SH, Elemento O, Zhang J, Zhuang ZW, Simons M and Hla T: ELAVL1 regulates alternative splicing of eIF4E transporter to promote postnatal angiogenesis. Proc Natl Acad Sci USA. 111:18309–18314. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Liu Y, Nie H, Ma X and Xu Z: Alternative splicing of inner-ear-expressed genes. Front Med. 10:250–257. 2016. View Article : Google Scholar : PubMed/NCBI
20	Lin L, Park JW, Ramachandran S, Zhang Y, Tseng YT, Shen S, Waldvogel HJ, Curtis MA, Faull RL, Troncoso JC, et al: Transcriptome sequencing reveals aberrant alternative splicing in Huntington's disease. Hum Mol Genet. 25:3454–3466. 2016. View Article : Google Scholar : PubMed/NCBI
21	Urbanski LM, Leclair N and Anczuków O: Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley Interdiscip Rev RNA. 9:e14762018. View Article : Google Scholar : PubMed/NCBI
22	Martinez-Montiel N, Rosas-Murrieta NH, Anaya Ruiz M, Monjaraz-Guzman E and Martinez-Contreras R: Alternative splicing as a target for cancer treatment. Int J Mol Sci. 19(pii): E5452018. View Article : Google Scholar : PubMed/NCBI
23	Dvinge H, Kim E, Abdel-Wahab O and Bradley RK: RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 16:413–430. 2016. View Article : Google Scholar : PubMed/NCBI
24	Sveen A, Kilpinen S, Ruusulehto A, Lothe RA and Skotheim RI: Aberrant RNA splicing in cancer; Expression changes and driver mutations of splicing factor genes. Oncogene. 35:2413–2427. 2016. View Article : Google Scholar : PubMed/NCBI
25	Shen S, Wang Y, Wang C, Wu YN and Xing Y: SURVIV for survival analysis of mRNA isoform variation. Nat Commun. 7:115482016. View Article : Google Scholar : PubMed/NCBI
26	Song J, Liu YD, Su J, Yuan D, Sun F and Zhu J: Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma. J Cell Physiol. 234:22753–22764. 2019. View Article : Google Scholar : PubMed/NCBI
27	Zhu GQ, Zhou YJ, Qiu LX, Wang B, Yang Y, Liao WT, Luo YH, Shi YH, Zhou J, Fan J and Dai Z: Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: A study based on large-scale sequencing data. Carcinogenesis. May 17–2019.doi: 10.1093/carcin/bgz073 (Epub ahead of print). View Article : Google Scholar
28	Zhu J, Chen Z and Yong L: Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol. 148:368–374. 2018. View Article : Google Scholar : PubMed/NCBI
29	Ryan M, Wong WC, Brown R, Akbani R, Su X, Broom B, Melott J and Weinstein J: TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 44:D1018–D1022. 2016. View Article : Google Scholar : PubMed/NCBI
30	Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, et al: A Comprehensive Pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell. 33:690–705.e9. 2018. View Article : Google Scholar : PubMed/NCBI
31	Piva F, Giulietti M, Burini AB and Principato G: SpliceAid 2: A database of human splicing factors expression data and RNA target motifs. Hum Mutat. 33:81–85. 2012. View Article : Google Scholar : PubMed/NCBI
32	Akaike H: Information theory and an extension of the maximum likelihood principle. 2nd Int. Sympo. on Information Theor, 1972. https://doi.org/10.1007/978-1-4612-0919-5_38
33	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
34	Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4:P32003. View Article : Google Scholar : PubMed/NCBI
35	Goebel G, Berger R, Strasak AM, Egle D, Müller-Holzner E, Schmidt S, Rainer J, Presul E, Parson W, Lang S, et al: Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Br J Cancer. 106:189–198. 2012. View Article : Google Scholar : PubMed/NCBI
36	Bhattacharya R, Mitra T, Ray Chaudhuri S and Roy SS: Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells. J Cell Biochem. 119:3373–3383. 2018. View Article : Google Scholar : PubMed/NCBI
37	Upheber S, Karle A, Miller J, Schlaugk S, Gross E and Reuning U: Alternative splicing of KAI1 abrogates its tumor-suppressive effects on integrin αvβ3-mediated ovarian cancer biology. Cell Signal. 27:652–662. 2015. View Article : Google Scholar : PubMed/NCBI
38	Markman M: Antineoplastic agents in the management of ovarian cancer: Current status and emerging therapeutic strategies. Trends Pharmacol Sci. 29:515–519. 2018. View Article : Google Scholar
39	He X, Ee PL, Coon JS and Beck WT: Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res. 10:4652–4660. 2004. View Article : Google Scholar : PubMed/NCBI
40	Sun Y, Li T, Ma K, Tian Z, Zhu Y, Chen F and Hu G: The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. Cancer Invest. 27:891–897. 2009. View Article : Google Scholar : PubMed/NCBI
41	Zhao H, Sun Q, Li L, Zhou J, Zhang C, Hu T, Zhou X, Zhang L, Wang B, Li B, et al: High expression levels of AGGF1 and MFAP4 predict primary platinum-based chemoresistance and are associated with adverse prognosis in patients with serous ovarian cancer. J Cancer. 10:397–407. 2019. View Article : Google Scholar : PubMed/NCBI
42	Liu R, Zeng Y, Zhou CF, Wang Y, Li X, Liu ZQ, Chen XP, Zhang W and Zhou HH: Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients. Sci Rep. 7:182017. View Article : Google Scholar : PubMed/NCBI
43	Matte I, Garde-Granger P, Bessette P and Piché A: Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer. Am J Cancer Res. 9:160–170. 2019.PubMed/NCBI